EyePoint, Inc. EYPT
At closeNov 3, 2026, 5:58 PM EST
After hours · Nov 3, 5:58 PM ET
- YTD
- -97.81%
- 1 year
- -96.79%
- Market cap
- 34.48M
- Revenue (ttm)
- 2.79M
- EPS (ttm)
- -3.75
- Shares out
- 83.84M
- Forward P/E
- -4.89
- YTD return
- -97.81%
- 1-year return
- -96.79%
- Volume
- 3.51M
- Avg volume
- 9.11M
- Open
- 0.3752
- Previous close
- 0.3748
- Day's range
- 0.3752 – 0.4126
- 52-week range
- 0.34 – 19.11
- Beta
- 1.74
- Analysts
- Strong Buy
- Price target
- 40.93 (+10134.7%)
- Earnings date
- Nov 4, 2026
30m +0.0027 (+0.73%)
Key statistics
- Enterprise value
- 1.25B
- PEG ratio
- 0.00
- Price / sales
- 443.56
- Price / book
- 37.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 161.70%
- Free cash flow
- -155.01M
- Total cash
- 45.26M
- Total debt
- 17.62M
- Return on equity
- -148.70%
- Short % of float
- 21.99%
- 50-day average
- 13.11
- 200-day average
- 14.14
Analyst view
Consensus: strong buy
- Target (low)
- 20.00
- Target (mean)
- 40.93
- Target (high)
- 68.00
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.921.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.8897 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -1.01 | -1.09 | -0.08 | -7.92% |
| May 6, 2026 | Mar 31, 2026 | -0.79 | -0.99 | -0.20 | -25.32% |
| Mar 4, 2026 | Dec 31, 2025 | -0.78 | -0.81 | -0.03 | -3.85% |
| Nov 5, 2025 | Sep 30, 2025 | -0.77 | -0.85 | -0.08 | -10.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.67 | -0.85 | -0.18 | -26.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Chardan Capital | main | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2026 | Stifel | init | — | Buy |
| Jul 1, 2026 | Chardan Capital | main | Buy | Buy |
| Jun 24, 2026 | Guggenheim | reit | Buy | Buy |
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eyepoint.bio
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT 
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy? 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT 
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky 
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT) 
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss 
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals 
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals 
RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1
Your note
Sign in to keep a note on EYPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDO GORAN A | Director | Purchase | Aug 20, 2024 | 13,150 |
| CORMORANT ASSET MANAGEMENT ,L.P | Unknown | Sale | Dec 3, 2025 | 0 |
| DICICCO WENDY FRANCES | Director | Purchase | Aug 19, 2024 | 9,967 |
| DUKER JAY S | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 9, 2026 | 187,025 |
| ELSTON GEORGE O | Chief Financial Officer | Conversion of Exercise of derivative security | May 21, 2026 | 121,691 |
| LANDIS JOHN B | Director | Conversion of Exercise of derivative security | Jan 2, 2025 | 21,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.62% | 8,296,375 | 122.37M | Mar 30, 2026 |
| Cormorant Asset Management, LP | 9.59% | 8,265,000 | 121.91M | Mar 30, 2026 |
| Blackrock Inc. | 8.66% | 7,463,197 | 110.08M | Jun 29, 2026 |
| Federated Hermes, Inc. | 6.59% | 5,681,052 | 83.80M | Jun 29, 2026 |
| Franklin Resources, Inc. | 5.86% | 5,048,598 | 74.47M | Mar 30, 2026 |
| Janus Henderson Group PLC | 4.18% | 3,601,168 | 53.12M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 3.21% | 2,771,487 | 40.88M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 2,600,860 | 38.36M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,033,206 | 29.99M | Jun 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 2.30% | 1,982,000 | 29.23M | Apr 29, 2026 |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 1.75% | 1,506,751 | 22.22M | Apr 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.44% | 1,245,583 | 18.37M | Mar 30, 2026 |